Medtronic HMS Plus Manuel De L'utilisateur page 153

HMS_Plus_EN_9.fm 4/17/12 6:44 pm
8.5 x 11.0 inches (215.9 mm x 279.4 mm)
Despotis GJ, Ikonomakou S, Levine L, Joiner-Maier D, Santoro SA, Joist JH.
Effects of platelets and white blood cells and antiplatelet agent c7E3 (ReoPro™) on
a new test of PAF procoagulant activity of whole blood. Thromb Res. 1997;86 (3):205.
Doty DB, Knott HW, Hoyt JL, Koepke JA. Heparin dose for accurate anticoagulation
in cardiac surgery. J Cardiovasc Surg. 1979;20:597.
Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height
and weight be known. Arch Intern Med. 1916;17:863.
Effeney DJ, Goldstone J, Chin D, Krupski WC, Ellis RJ. Intraoperative
anticoagulation in cardiovascular surgery. Surgery. 1971;90:1068.
Esposito RA, Culliford AT, Colvin SB, Lackner H, Spencer FC. Heparin resistance
during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac
Cardiovasc Surg. 1983;85:346.
Fox DJ, Gaines J, Reed G. Vehicles of heparin management: a comparison. J
Extracorp Tech. 1979;1:137.
Diem K, Lenter C, eds. Geigy Pharmaceuticals Scientific Tables. 7th ed. Ardsley,
New York: Geigy Pharmaceuticals; 1970.
Glynn MF. Heparin monitoring and thrombosis. Am J Clin Pathol. 1979;71:397.
Gollub S. Heparin rebound in open-heart surgery. Surg Gynecol Obstet.
1967;124:33.
Gourin A, Streisman R, Stuckey JH. Total cardiopulmonary protamine sulfate.
J Thorac Cardiovasc Surg. 1971;61:160.
Gravlee GP, Angert KC, Tucker WY, Case LD, Wallenhaupt SL, Cordell AR. Early
anticoagulation peak and rapid distribution after intravenous heparin. Anesthesiology.
1988;58:126.
Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated
coagulation time. Anesth Analg. 1988;67:469.
Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436.
Hill AG, Lefrak EA. Monitoring heparin and protamine therapy during
cardiopulmonary bypass procedures. AMSECT Proc. 1978:6:8.
Horkay F, Martin P, Rajah SM, Walker DR. Response to heparinization in adults and
children undergoing cardiac operations. Ann Thorac Surg. 1992;53:822.
Kemna GD, Bowie JE. Heparin protamine management for cardiopulmonary bypass
patients with abnormal heparin dose response. Proc Am Acad Cardiovasc Perfus.
1985;6:89.
Kopriva CJ, Spreenivasan N, Stefansson S, Farrell DT, Shaffer WB, Geha AS.
Hypothermia can cause errors in activated coagulation time. Anesthesiology.
1980;53(3):S85.
Lefemine AA, Lewis M. Activated clotting time for control of anticoagulation during
surgery. Am Surg. 1985;51:274.
Lindblad B, Borgstrom A, Wakefield TW, Whitehouse WM, Stanley JC.
Haemodynamic and haematologic alterations with protamine reversal of
anticoagulation: Comparison of standard heparin and a low molecular weight heparin
fragment. Eur J Vasc Surg. 1987;1:181.
Mochizuki T, Olson PJ, Ramsay JG, Szlam F, Levy JH. Does protamine reversal
affect platelet function? Anesth Analg. 1997:84 SCA 35.
86508002 Rev. 1A
Medtronic Confidential
Références
Manuel de l'utilisateur HMS Plus
CS0026
9-3